ReviewMedical gas research2026
Medical gases and long-term oxygen therapy: reducing the chronic obstructive pulmonary disease burden in aging populations in Sub-Saharan Africa.
Review in Medical gas research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive pulmonary disease (COPD) is a major global health challenge, disproportionately affecting aging populations in low- and middle-income countries, including Sub-Saharan Africa (SSA). With an increasing prevalence driven by indoor air pollution, tobacco use, and occupational hazards, COPD remains underdiagnosed underdiagnosed and undertreated in the region due to inadequate healthcare infrastructure and resource constraints. This review highlights the critical role of medical gases, particularly long-term oxygen therapy (LTOT), in managing COPD, improving quality of life, and reducing mortality in patients with severe hypoxemia. Although LTOT is well-established in high-income countries, its implementation in SSA faces significant barriers, including limited access, cost, and insufficient awareness. This review analyzes COPD management, LTOT benefits, healthcare policies, and aging demographics in SSA, focusing on experimental studies and synthesizing data for coherence. Relevant articles in English published from 2014 to 2025 were retrieved from PubMed, Scopus, and WHO. Through a comprehensive analysis of the epidemiology of COPD in SSA, the challenges of integrating LTOT, and successful case studies from comparable regions, this review identifies key opportunities for addressing these gaps. Recommendations include strengthening healthcare infrastructure, fostering policy frameworks for LTOT integration, leveraging community engagement, and enhancing patient education. By addressing these challenges holistically and fostering regional and global collaborations, SSA can mitigate the growing burden of COPD and improve health outcomes for its aging populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.